Monday August 13, 2018 0 comments
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced the pricing of an underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 million shares of common stock, at a combined purchase price of $0.40 per share of common stock and accompanying warrant, with anticipated gross proceeds of $8 million.
The warrants are exercisable six months after issuance at a price of $0.40 per share of common stock and have a term of five years commencing six months after issuance, Ampio said.
The offering is expected to close on or about Aug. 13, 2018, subject to customary closing conditions.
All of the securities in the offering are to be sold by Ampio. Ampio said it intends to use net proceeds from the offering for working capital and general corporate purposes, including continued preclinical development of Ampion and funding an Ampion clinical trial, if required.
Canaccord Genuity is acting as sole book-running manager for the offering, the company said.
The sale of the common stock and the accompanying warrants to purchase shares of common stock is being offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017.
A final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC, will be available on the SEC's website at www.sec.gov and will form a part of the effective registration statement.
Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained, when available, by contacting Canaccord Genuity LLC, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Syndicate Department, by telephone at (617) 371-3900 or by e-mail at [email protected]